Authors
Latest:
Medical Ethics in Pediatric OncologyEveryone, at every level, is checking, rechecking, thinking, researching, asking questions, discussing, analyzing, and trying to help patients.
Latest:
Work-Life Balance of a Hem/Onc FellowI am a member of the cohort of 30-something single Indian women who were not lucky enough to snag the right guy during med school, and perhaps am not genetically engineered to be good at dating and studying simultaneously.
Latest:
Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple MyelomaNitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.
Latest:
Dr. Bahlis on Updated Data From the MAIA Trial in Multiple MyelomaNizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.
Latest:
Dr Tannir on Unmet Needs in the Treatment of Rare Kidney TumorsNizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.
Latest:
Dr Biran on the IMROZ Trial in Newly Diagnosed, Transplant-Ineligible Multiple MyelomaNoa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.
Latest:
Dr. Kauff on Challenges in Treating Uterine CancerNoah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.
Latest:
Dr. Federman on Challenges With Treating AYA Patients With SarcomaNoah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the challenges associated with treating adolescent and young adult (AYA) patients with sarcoma.
Latest:
Dr. Kornblum on Results of PrECOG 0102 in Breast CancerNoah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.
Latest:
Dr. Frey on the Utility of CART22-65s with huCART19 in Relapsed/Refractory ALLNoelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.
Latest:
Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro NakamuraIn this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.
Latest:
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral CentersPanelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.
Latest:
Dr. Hashemi Sadraei Discusses Biomarkers in HPV-Induced TumorsNooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.
Latest:
Lymph Nodes Overlooked in Ovarian Cancer PatientsWomen with early-stage ovarian cancer were nearly twice as likely to die if they did not have recommended staging biopsies of pelvic and aortic lymph nodes
Latest:
Dr. Sharpless on Managing Toxicities With Nivolumab and Ipilimumab in MelanomaNorman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses how oncologists can best manage toxicities associated with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.
Latest:
Northwell, The START Center for Cancer Research to Form Strategic PartnershipNew START early-phase clinical trial site brings advanced cancer research to Northwell’s Cancer Institute, increases patient access
Latest:
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal CancerStudies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
Latest:
Dr. Danciu on Prescreening and Identifying Breast Cancer SurvivorsOana C. Danciu, MD, assistant professor of Medicine, Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, discusses a study examining a team-based approach to prescreen and identify breast cancer survivors using a survivorship care plan.
Latest:
December 2011: Trials in ProgressThe Trials in Progress section supploes summaries of ongoing research in a broad range of cancer types.
Latest:
Dr Landgren on the Management of Newly Diagnosed Multiple Myeloma TreatmentC. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.
Latest:
Dr. Frankfurt on the Future of AML TreatmentsOlga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.
Latest:
Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian CancerOliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.
